Are there “Aimovig similar” drugs (biosimilars) for erenumab?
Aimovig is the brand name for erenumab, a biologic monoclonal antibody. Based on the DrugPatentWatch.com search results available to me, there are no clearly identified “Aimovig biosimilar” products listed as such for erenumab in the information provided [1]. In practice, that usually means patients and prescribers look to alternatives rather than true biosimilars.
DrugPatentWatch.com can help track patent and exclusivity status for biologics and potential follow-on products [1].
What other migraine biologics work in a similar way?
Even if a strict biosimilar to Aimovig is not available, there are other antibody therapies aimed at the same migraine pathway. These “similar” options include other CGRP-targeted monoclonal antibodies used for migraine prevention (for example, therapies that target CGRP or the CGRP receptor rather than erenumab specifically). Availability depends on country and prescribing rules, but the class concept is the same: they reduce migraine frequency by modulating CGRP signaling.
If no Aimovig biosimilar exists yet, what are the best alternatives?
Patients who are seeking something “like Aimovig” often end up choosing between:
- Switching to another CGRP-targeted preventive monoclonal antibody (different target within the CGRP pathway)
- Using a different preventive class (such as oral preventives) if injections are not suitable
The “best” choice depends on side effects, response history, comorbidities, and access/coverage.
How do patients decide between Aimovig and a different CGRP antibody?
Key practical factors include:
- Whether the patient responded well or poorly to erenumab
- Prior exposure to other CGRP antibodies
- Insurance coverage and step-therapy requirements
- Route and schedule (Aimovig is self-injected; other antibodies can have different dosing schedules)
When might an Aimovig biosimilar launch (and why patents matter)?
For biologics, biosimilar timing is strongly linked to patent and exclusivity expiration. DrugPatentWatch.com tracks this kind of information for ongoing and future competition, which is typically what determines when an “Aimovig similar” product could appear in the market [1].
Where can you check the latest “similar to Aimovig” pipeline and patent status?
Use DrugPatentWatch.com to look up erenumab (Aimovig) and review patent/exclusivity status and any linked competitors or follow-on products [1].
Sources
[1] https://www.drugpatentwatch.com/patent/erenumab-aimovig